Myofilament-level effects of aficamten increase diastolic chamber volumes and maintain cardiac output through preserved length-dependent force generation in healthy rat and canine myocardium
{{output}}
Clinical trial experience supports the use of myosin inhibitors in hypertrophic cardiomyopathy (HCM), while early proof-of-concept studies suggest potential benefit in selected patients with heart failure with preserved ejection fraction (HFpEF). However, conc... ...
